

Independent Advisory Group (Tayside Breast Cancer) Remit, Terms of Reference and Membership

Remit

To carefully consider the individual recommendations made in the Healthcare Improvement Scotland report “Clinical Management of Breast Cancer in NHS Tayside” and the “Clinical Risk Assessment” of that report produced by the Immediate Review Group. To advise the Chief Medical Officer on how these recommendations can be implemented to ensure safe and effective delivery of cancer medicines in the Northern Cancer Alliance (NCA – previously known as NoSCAN). The group will aim to produce this advice to CMO in June 2019.

Terms of Reference

The CMO has commissioned Professor Aileen Keel CBE, Director of IHDP and Chair of the Scottish Cancer Taskforce to independently consider the findings of both the HIS report “Clinical Management of Breast Cancer in NHS Tayside published on 1 April 2019 and the Clinical Risk Assessment of the Healthcare Improvement Scotland Report “Clinical Management of Breast Cancer in NHS Tayside” published by the CMO/CPO appointed Immediate Review Group on 16 April 2019.

Purpose

This independent group will advise the CMO on the implementation of the recommendations in the HIS report and Clinical Risk Assessment. The group will make further recommendations aimed at rebuilding and maintaining public confidence in the safe and effective delivery of cancer medicines in the Northern Cancer Alliance, with a particular focus on:

- Current cancer medicines governance processes in the NCA, including the development of Cancer Management Guidelines (CMGs), and the processes for achieving clinical consensus in this context across the network.
- Escalation procedures when consensus is not achieved.
- Consideration of how effective and meaningful executive engagement from constituent boards within the NCA can be developed and maintained
- Any further actions that need to be taken in relation to the wider operations of the NCA, to ensure full engagement of its constituent Boards, as well as consideration of how best to incorporate the views of patients into its work.

In undertaking this work the Chair will meet with affected patients to consider the impact on them.

Membership

Name	Representing
Aileen Keel	Chair
Alan Rodger	Retired Former Medical Director, Beatson
David Dunlop	Scottish Government Clinical Advisor
Grant Archibald	CE, NHS Tayside
Lorraine Cowie	NCA Manager NHS Grampian
Boyd Peters	Highland NHS Board
Aileen Muir	Lead Pharmacist for Governance NHS GG&C
James Mandor	NHS Lothian (lead clinician)
David Cameron	Clinical Director, Edinburgh University
Ian Rudd	Director of Pharmacy, NHS Grampian
Laura McIver	Chief Pharmacist NHS HIS
Amanda Croft	CE NHS Grampian
AN OTHER	NHS Tayside (successor of Sami Shimi)